
ETRA Stock Forecast & Price Target
ETRA Analyst Ratings
Bulls say
Electra Therapeutics is compelling because its first-in-class SIRP-targeted platform has already shown human proof-of-concept, with ipsoprubart delivering 100% 8-week overall survival and 100% overall response in 12 frontline mHLH patients, including 10 partial responses and two modified complete responses. The company is addressing a severe, underserved market where U.S. diagnosed incidence reached about 12,600 in 2025 and could approach nearly 17,500 in 2028, supporting premium orphan pricing and meaningful commercial upside. Its outlook is further strengthened by Breakthrough Therapy and PRIME designations, a registrational program underway, a cash position of $97.7 million as of June 30, 2026, and an additional platform asset, ELA822, that broadens the pipeline beyond sHLH.
Bears say
Electra Therapeutics is a late clinical-stage biopharmaceutical company with no approved products and no projected revenue in either 2026 or 2027, leaving valuation dependent entirely on uncertain clinical progress rather than existing cash generation. The company faces substantial near-term cash burn, with projected R&D of $86.5 million in 2026 and $120 million in 2027, operating losses of $108.5 million and $160 million, and free cash outflows of about $105.4 million and $154.8 million, respectively. Its lead asset, ipsoprubart, relies on a single-arm SURPASS design and small uncontrolled datasets, while ELA822 is still early-stage, so clinical, regulatory, reimbursement, and execution risks could delay any U.S. launch before 2030 and force additional financing.
This aggregate rating is based on analysts' research of Electra Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ETRA Analyst Forecast & Price Prediction
Start investing in ETRA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Electra Therapeutics Inc (ETRA) Forecast
ETRA Analyst Forecast & Price Prediction
Start investing in ETRA
Order type
Buy in
Order amount
Est. shares
0 shares